Price (delayed)
$1.9
Market cap
$27.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.37
Enterprise value
-$10.88M
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically
There are no recent dividends present for ABIO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.